A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is sure to face legal challenges, experts say.

The company established a new protocol for the study and will advance its drug response predictor as a companion diagnostic.

The agency will allow BMS to discontinue REMS programs for both therapies and reduce certain patient monitoring requirements.

The firm will take a different reimbursement strategy for the test than its prior owner Biocept, which stopped selling it after filing for bankruptcy in 2023.